National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Daratumumab (Darzalex®) in combination with lenalidomide and dexamethasone

Daratumumab for use in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma wo have received at least one prior therapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 09/10/2017
Rapid review completed 27/11/2017
Rapid Review outcome A full pharmacoeconomic evaluation is recommended

 

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.